Three months ago, a group of practitioners published a quiet result that, in hindsight, marks a real inflection point on why glp-1 drugs are reshaping more than just weight loss.
What's changing
What's tricky is that the leading indicators are noisy. Vendor revenue is up, but so is churn. Talent moves both ways. Job postings list contradictory requirements. The strongest signal is what experienced practitioners do with their own time and money — and increasingly, they're betting on the opposite of last year's consensus.
Why it matters
Three quiet trends are converging: cheaper compute, better tooling, and a new generation of operators who grew up with these tools as defaults. Each was a slow burn on its own. Together they compound, and that compounding is what most quarterly forecasts will miss.
What to do about it
Three quiet trends are converging: cheaper compute, better tooling, and a new generation of operators who grew up with these tools as defaults. Each was a slow burn on its own. Together they compound, and that compounding is what most quarterly forecasts will miss.
- Adopt early — the cost of waiting is higher than the cost of failing fast.
- Measure honestly — pick two metrics, ignore the rest for the first month.
- Talk to users — the gap between assumption and reality is wider than ever.
The takeaway
We don't need another framework — we need a better default. For most teams, the right move is to test the contrarian position with one project and let the results decide.
